<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/395F850A-031E-45AD-817A-4C46D042B92C"><gtr:id>395F850A-031E-45AD-817A-4C46D042B92C</gtr:id><gtr:name>University of Cincinnati</gtr:name><gtr:address><gtr:line1>University of Cincinnati</gtr:line1><gtr:line2>2624 Clifton Avenue</gtr:line2><gtr:postCode>OH 45221-0</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/6083E7FB-0220-4F5F-97B0-7F6113B49A0C"><gtr:id>6083E7FB-0220-4F5F-97B0-7F6113B49A0C</gtr:id><gtr:name>MRC Unit, The Gambia</gtr:name><gtr:address><gtr:line1>MRC Laboratories, The Gambia</gtr:line1><gtr:line2>Atlantic Road PO Box 273</gtr:line2><gtr:line4>Fajara</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Gambia</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/395F850A-031E-45AD-817A-4C46D042B92C"><gtr:id>395F850A-031E-45AD-817A-4C46D042B92C</gtr:id><gtr:name>University of Cincinnati</gtr:name><gtr:address><gtr:line1>University of Cincinnati</gtr:line1><gtr:line2>2624 Clifton Avenue</gtr:line2><gtr:postCode>OH 45221-0</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/E89DF462-9EA4-4042-B006-DC19F73B5B9E"><gtr:id>E89DF462-9EA4-4042-B006-DC19F73B5B9E</gtr:id><gtr:firstName>Beate</gtr:firstName><gtr:surname>Kampmann</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/A46886AF-06E9-49E1-BF77-96A53F3F6C48"><gtr:id>A46886AF-06E9-49E1-BF77-96A53F3F6C48</gtr:id><gtr:firstName>Ed</gtr:firstName><gtr:surname>Clarke</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C166EF2D-FBDF-4D1F-A789-7379B587FF9C"><gtr:id>C166EF2D-FBDF-4D1F-A789-7379B587FF9C</gtr:id><gtr:firstName>Martin</gtr:firstName><gtr:surname>Antonio</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/D7DAD97D-0401-422C-9413-26C12208AF06"><gtr:id>D7DAD97D-0401-422C-9413-26C12208AF06</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Goldblatt</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3D953AD6-A053-4BBD-83BC-4E1B399B1756"><gtr:id>3D953AD6-A053-4BBD-83BC-4E1B399B1756</gtr:id><gtr:firstName>David</gtr:firstName><gtr:surname>Jeffries</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/CF99A386-990A-49B0-9577-00E756482588"><gtr:id>CF99A386-990A-49B0-9577-00E756482588</gtr:id><gtr:firstName>Koen</gtr:firstName><gtr:surname>Peeters</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MC_EX_MR%2FM007529%2F1"><gtr:id>9E6C4B89-09F3-4064-B3A0-F57D796FA4A7</gtr:id><gtr:title>A randomised, controlled, laboratory observer-blind, phase 3 trial to evaluate the effects of maternal or neonatal pneumococcal conjugate vaccination on pneumococcal carriage in infants up to nine months of age</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MC_EX_MR/M007529/1</gtr:grantReference><gtr:abstractText>A bacteria (or germ) called pneumococcus, which causes pneumonia, meningitis and blood stream infections, is responsible for hundreds of thousands of deaths as well as a tremendous burden of serious disease in babies and children each year. Children are already vaccinated against the infection at around 2, 3 and 4 months of age but this leaves them susceptible to infection in very early life, as soon as they are borne. In settings such as The Gambia, pneumococcus 'colonizes' the back of the nose (it lives there without causing disease in most cases) at very high level over these first few months.
This trial aims to find out whether giving mothers the vaccine against pneumococcus in the third trimester of pregnancy may allow them to pass protection (antibodies) to the newborn. Also whether vaccinating a baby as soon as they are born may protect them in a similar way.
If either of these approaches are successful this might provide important decision makers, such as the World Health Organisation, with new ways to prevent disease and serious infections in newborn babies.</gtr:abstractText><gtr:technicalSummary>This phase 3, randomised trial will examine the role of vaccinating mothers in the third trimester of pregnancy or neonates immediately after birth with a pneumococcal conjugate vaccine (Prevenar 13? - PCV13) in order to prevent carriage of pneumococcus in the nasopharynx between birth and 20 weeks of age. 
Carriage of pneumococcus in the nasopharynx is a prerequisite for disease (pneumonia, septicaemia and meningitis) and, in the trial, prevention of carriage is a used as a surrogate for prevention of disease. The overall objective of the trial is to find new ways to combat these serious infections which occur in early life, before children are routinely vaccinated.
600 expectant mothers will be recruited in the third trimester of pregnancy and their subsequent born infants will be followed up until the age of 9 months. The mothers will be randomized either to a 'Maternal' group who will receive PCV13 in pregnancy, a 'Neonatal' group, the infants of whom will receive the vaccine at birth or a 'Control' group who's infants will receive the vaccine according to the normal schedule at 2, 3 and 4 months of age.
If the trial demonstrates either of these alternative approaches significantly reduces pneumococcal carriage in early life the potential implications in terms of modifying WHO vaccination policy are very significant.</gtr:technicalSummary><gtr:fund><gtr:end>2017-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>0</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cincinnati</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Viral illnesses in infants and mothers in the PROPEL trial</gtr:description><gtr:id>96490335-526B-4586-BB55-7B5522F55012</gtr:id><gtr:impact>Awaited</gtr:impact><gtr:partnerContribution>Provision of laboratory supplies and expertise</gtr:partnerContribution><gtr:piContribution>Provision of samples</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Child Health</gtr:department><gtr:description>ICH London Goldblatt lab</gtr:description><gtr:id>98F7EA95-3FAE-43C9-9F02-7DC74C561CB5</gtr:id><gtr:impact>1 shared PhD studentship, 
scientific workshop at MRC The Gambia
input into senior appointments</gtr:impact><gtr:partnerContribution>scientific exchange re pneumococcal immunisation policies, practice and research, sharing of reagents and assay development</gtr:partnerContribution><gtr:piContribution>scientific exchange re pneumococcal immunisation policies, practice and research, sharing of reagents and assay development</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>195000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Maternal Men A vaccination</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>Meningitis Research Foundation</gtr:fundingOrg><gtr:id>9C32B15B-DB2E-46BA-8476-AB32A59FF749</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Maternal Immunization Pharmacovigilance - Landscape Review - A Roadmap for Program Development in Low and Middle Income Countries</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>F079419A-F375-4AA2-8A20-89EE451E17E3</gtr:id><gtr:impact>The document resulting from this advisory committee consultation is expected to be used to focus future work to measure health impacts in expectant mothers receiving vaccines in low and middle income countries as well as to direct the development of the otherwise fledgling regulatory framework globally</gtr:impact><gtr:type>Participation in a advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Participation in NIH/BMGF advisory meeting - Harmonization of Safety Reporting in Immunizations in Pregnancy</gtr:description><gtr:geographicReach>Africa</gtr:geographicReach><gtr:id>A243FA0A-1EF7-4C5E-A7F0-70E80EFAD328</gtr:id><gtr:impact>The meeting drove the further expansion of the use of harmonized terms for safety reporting in pregnancy</gtr:impact><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>Prevenar13 is licensed in infants, children and adults but is not licensed in pregnancy. This trial is testing the safety and efficacy against pneumococcal nasopharyngeal carriage of the vaccine in pregnant women and newborns</gtr:description><gtr:id>2D100CF1-FDCE-4EED-B6C2-00F140976F85</gtr:id><gtr:impact>The trial is currently underway and data has yet to be analysed.</gtr:impact><gtr:stage>Late clinical evaluation</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Prevenar13 (licensed vaccine) for use in expectant mothers (unlicensed indication)</gtr:title><gtr:type>Therapeutic Intervention - Vaccines</gtr:type><gtr:url>https://clinicaltrials.gov/ct2/show/NCT02628886</gtr:url><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Maternal vaccination trials in low income countries require the development of significant research infrastructure. IN particular we have established an antenatal ultrasound facility within which to undertake gestational ultrasound assessments (not otherwise available in the country) and a framework for the capture and reporting of safety outcomes</gtr:description><gtr:id>82BA20E1-FE05-4AC7-A490-397B927E7431</gtr:id><gtr:impact>The platform will be used for future research in this field in The Gambia and is also likely (based on a planned publication related to the development of the platform) to guide researchers elsewhere</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>The development of a research platform within which to undertake maternal vaccination safety and immunogenicity trials in The Gambia</gtr:title><gtr:type>Improvements to research infrastructure</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/DA591BAE-88DC-47C0-B7C4-A8929D025180"><gtr:id>DA591BAE-88DC-47C0-B7C4-A8929D025180</gtr:id><gtr:title>Safety and immunogenicity of inactivated poliovirus vaccine when given with measles-rubella combined vaccine and yellow fever vaccine and when given via different administration routes: a phase 4, randomised, non-inferiority trial in The Gambia.</gtr:title><gtr:parentPublicationTitle>The Lancet. Global health</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1d427600d7a231127ff9995f95c66a3e"><gtr:id>1d427600d7a231127ff9995f95c66a3e</gtr:id><gtr:otherNames>Clarke E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2214-109X</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/25BC77F2-059E-44E5-A2B4-A353928E4078"><gtr:id>25BC77F2-059E-44E5-A2B4-A353928E4078</gtr:id><gtr:title>Maternal and neonatal pneumococcal vaccination - where are we now?</gtr:title><gtr:parentPublicationTitle>Expert review of vaccines</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/1d427600d7a231127ff9995f95c66a3e"><gtr:id>1d427600d7a231127ff9995f95c66a3e</gtr:id><gtr:otherNames>Clarke E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1476-0584</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_EX_MR/M007529/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>D8F3A27D-084A-40BB-A046-087DACE23410</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>3.4  Vaccines</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>